See more : Soulbrain Co., Ltd. (357780.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Apyx Medical Corporation (APYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apyx Medical Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- Manufatura de Brinquedos Estrela S.A. (ESTR3.SA) Income Statement Analysis – Financial Results
- Independent Bank Corporation (IBCP) Income Statement Analysis – Financial Results
- Internet Thailand Public Company Limited (INET.BK) Income Statement Analysis – Financial Results
- Alliance Entertainment Holding Corporation (AENTW) Income Statement Analysis – Financial Results
- Chengtun Mining Group Co., Ltd. (600711.SS) Income Statement Analysis – Financial Results
Apyx Medical Corporation (APYX)
About Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 52.35M | 44.51M | 48.52M | 27.71M | 28.15M | 16.69M | 38.88M | 36.63M | 29.52M | 27.68M | 23.66M | 27.67M | 25.41M | 24.23M | 26.95M | 28.10M | 28.78M | 26.68M | 20.21M | 20.50M | 16.55M | 12.45M | 11.48M | 9.94M | 9.60M | 8.44M | 7.37M | 7.49M | 5.52M |
Cost of Revenue | 18.59M | 15.38M | 14.92M | 10.21M | 9.03M | 5.89M | 19.12M | 18.71M | 16.96M | 18.69M | 14.46M | 16.34M | 14.68M | 14.24M | 15.10M | 16.25M | 17.46M | 16.08M | 12.65M | 12.51M | 9.43M | 7.19M | 5.72M | 4.60M | 4.59M | 5.27M | 4.14M | 4.13M | 3.22M |
Gross Profit | 33.76M | 29.13M | 33.60M | 17.50M | 19.13M | 10.79M | 19.76M | 17.92M | 12.56M | 8.99M | 9.20M | 11.33M | 10.73M | 9.99M | 11.85M | 11.85M | 11.32M | 10.60M | 7.56M | 7.98M | 7.12M | 5.26M | 5.76M | 5.34M | 5.01M | 3.17M | 3.23M | 3.35M | 2.31M |
Gross Profit Ratio | 64.49% | 65.45% | 69.26% | 63.17% | 67.94% | 64.68% | 50.82% | 48.91% | 42.54% | 32.48% | 38.88% | 40.96% | 42.23% | 41.22% | 43.98% | 42.17% | 39.32% | 39.74% | 37.41% | 38.94% | 43.00% | 42.23% | 50.15% | 53.74% | 52.19% | 37.53% | 43.85% | 44.77% | 41.76% |
Research & Development | 4.84M | 4.54M | 4.32M | 3.92M | 3.81M | 2.47M | 2.46M | 2.62M | 2.16M | 1.42M | 1.26M | 1.33M | 1.20M | 1.85M | 2.08M | 2.06M | 1.64M | 1.19M | 985.81K | 907.39K | 717.35K | 693.71K | 463.13K | 513.02K | 379.83K | 183.17K | 96.74K | 105.70K | 121.90K |
General & Administrative | 48.87M | 48.15M | 43.73M | 33.67M | 36.23M | 21.18M | 21.05M | 19.09M | 17.38M | 13.43M | 9.96M | 8.96M | 10.30M | 9.60M | 9.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 2.30M | 1.30M | 800.00K | 1.50M | 800.00K | 11.37M | 8.57M | 8.42M | 6.69M | 4.89M | 4.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 48.87M | 48.15M | 43.73M | 33.67M | 36.23M | 21.18M | 21.05M | 19.09M | 17.38M | 13.43M | 9.96M | 8.96M | 10.30M | 9.60M | 9.06M | 8.50M | 7.57M | 6.79M | 6.01M | 5.76M | 5.60M | 4.91M | 4.71M | 3.90M | 6.46M | 1.75M | 0.00 | 1.34M | 1.18M |
Other Expenses | -2.69M | 509.00K | -373.00K | 479.00K | -382.00K | -203.00K | -11.37M | -8.57M | -8.42M | -6.69M | -4.89M | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 161.19K | 39.29K | 81.91K | 124.45K | 0.00 | 396.81K | 321.17K | 2.15M | 2.80M | 1.43M | 1.22M |
Operating Expenses | 51.02M | 52.69M | 48.05M | 37.59M | 40.04M | 23.65M | 23.50M | 21.71M | 19.54M | 14.84M | 11.22M | 10.29M | 11.50M | 11.45M | 11.14M | 10.56M | 9.21M | 7.98M | 7.16M | 6.70M | 6.40M | 5.73M | 5.18M | 4.81M | 7.16M | 4.09M | 2.89M | 2.87M | 2.53M |
Cost & Expenses | 69.61M | 68.07M | 62.97M | 47.79M | 49.07M | 29.55M | 42.62M | 40.42M | 36.51M | 33.53M | 25.69M | 26.63M | 26.18M | 25.70M | 26.24M | 26.81M | 26.67M | 24.05M | 19.81M | 19.22M | 15.84M | 12.92M | 10.90M | 9.41M | 11.75M | 9.36M | 7.03M | 7.01M | 5.74M |
Interest Income | 921.00K | 157.00K | 11.00K | 241.00K | 1.39M | 616.00K | 0.00 | 0.00 | 1.00K | 0.00 | 7.00K | 0.00 | 12.00K | 0.00 | 24.36K | 48.76K | 142.72K | 103.09K | 46.96K | 3.26K | 2.98K | 5.21K | 10.11K | 28.75K | 0.00 | 4.16K | 0.00 | 0.00 | 0.00 |
Interest Expense | 2.48M | 15.00K | 10.00K | 46.00K | 8.00K | 104.00K | 136.00K | 158.00K | 158.00K | 151.00K | 237.00K | 232.00K | 249.00K | 223.00K | 76.37K | 58.46K | 2.47K | 16.16K | 22.70K | 15.09K | 34.06K | 48.45K | 70.69K | 66.80K | 0.00 | 103.84K | 0.00 | 75.80K | 68.70K |
Depreciation & Amortization | 692.00K | 890.00K | 903.00K | 887.00K | 754.00K | 669.00K | 696.00K | 734.00K | 812.00K | 876.00K | 827.00K | 857.00K | 925.00K | 1.01M | 1.05M | 973.07K | 770.83K | 529.26K | 545.88K | 395.12K | 314.68K | 274.88K | 524.24K | 396.81K | 321.17K | 787.09K | 311.14K | 260.60K | 171.00K |
EBITDA | -18.11M | -22.01M | -13.91M | -18.48M | -19.07M | -13.92M | -13.01M | -3.79M | -4.37M | -12.25M | -3.68M | 1.93M | 1.19M | -1.23M | 1.79M | 3.81M | 2.88M | 3.15M | 949.84K | 1.67M | 978.14K | -199.02K | 1.16M | 926.71K | 947.21K | -133.07K | 650.72K | 741.00K | -48.50K |
EBITDA Ratio | -34.60% | -51.44% | -30.53% | -69.87% | -70.69% | -78.28% | -9.62% | -10.35% | -23.67% | -21.13% | -10.17% | 6.88% | 3.62% | 1.29% | 6.64% | 2.74% | 10.00% | 11.82% | 4.70% | 8.17% | 6.70% | -0.62% | 9.21% | 9.24% | -19.07% | -1.83% | 8.36% | 9.75% | -1.92% |
Operating Income | -17.26M | -23.56M | -14.45M | -20.08M | -20.91M | -13.60M | -5.27M | -3.79M | -6.99M | -5.85M | -3.67M | 1.05M | -18.00K | -2.75M | 714.85K | 1.29M | 2.11M | 2.62M | 403.97K | 1.28M | 712.40K | -473.90K | 583.58K | 529.90K | -2.15M | -920.16K | 339.58K | 480.40K | -219.50K |
Operating Income Ratio | -32.97% | -52.94% | -29.78% | -72.47% | -74.28% | -81.51% | -13.54% | -10.35% | -23.67% | -21.13% | -15.49% | 3.78% | -0.07% | -11.36% | 2.65% | 4.60% | 7.32% | 9.84% | 2.00% | 6.24% | 4.30% | -3.81% | 5.08% | 5.33% | -22.38% | -10.90% | 4.61% | 6.42% | -3.98% |
Total Other Income/Expenses | -4.02M | 651.00K | -372.00K | 674.00K | 1.03M | -1.09M | -8.57M | -94.00K | 1.64M | -7.44M | -2.29M | -212.00K | 50.00K | 290.00K | -52.01K | 1.49M | 140.25K | 86.93K | 24.26K | -11.83K | -31.08K | -40.87K | -431.47K | 8.79K | 3.25K | -77.88K | -240.39K | -64.80K | 65.40K |
Income Before Tax | -21.28M | -22.91M | -14.82M | -19.41M | -19.91M | -13.27M | -5.22M | -3.89M | -5.35M | -13.29M | -5.95M | 834.00K | 32.00K | -2.46M | 662.84K | 2.78M | 2.25M | 2.71M | 428.22K | 1.27M | 681.32K | -514.77K | 200.59K | 538.69K | -2.14M | -998.05K | 99.19K | 415.60K | -154.10K |
Income Before Tax Ratio | -40.65% | -51.47% | -30.55% | -70.04% | -70.72% | -79.53% | -13.42% | -10.61% | -18.11% | -47.99% | -25.16% | 3.01% | 0.13% | -10.16% | 2.46% | 9.88% | 7.81% | 10.16% | 2.12% | 6.18% | 4.12% | -4.14% | 1.75% | 5.42% | -22.35% | -11.82% | 1.35% | 5.55% | -2.79% |
Income Tax Expense | -2.43M | 367.00K | 380.00K | -7.50M | -260.00K | -3.78M | -156.00K | 64.00K | 25.00K | 4.00M | -1.61M | 217.00K | -77.00K | -927.00K | 67.32K | 945.42K | -148.84K | 47.57K | 32.02K | -272.72K | 31.08K | 40.87K | -211.19K | 29.27K | 35.81K | 77.88K | 240.39K | 8.30K | -65.40K |
Net Income | -18.71M | -23.28M | -15.20M | -11.91M | -19.65M | 64.01M | -5.06M | -3.95M | -5.37M | -17.28M | -4.34M | 617.00K | 109.00K | -1.54M | 595.52K | 1.83M | 2.40M | 2.68M | 406.21K | 1.51M | 681.32K | -514.77K | 784.29K | 500.63K | -2.18M | -998.05K | 99.19K | 407.30K | -154.10K |
Net Income Ratio | -35.75% | -52.30% | -31.33% | -42.96% | -69.79% | 383.61% | -13.02% | -10.78% | -18.19% | -62.43% | -18.34% | 2.23% | 0.43% | -6.34% | 2.21% | 6.52% | 8.34% | 10.06% | 2.01% | 7.38% | 4.12% | -4.14% | 6.83% | 5.04% | -22.75% | -11.82% | 1.35% | 5.44% | -2.79% |
EPS | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.93 | -0.16 | -0.14 | -0.22 | -0.98 | -0.25 | 0.04 | 0.01 | -0.09 | 0.04 | 0.11 | 0.15 | 0.19 | 0.03 | 0.11 | 0.05 | -0.04 | 0.06 | 0.04 | -0.16 | -0.07 | 0.01 | 0.05 | -0.04 |
EPS Diluted | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.86 | -0.16 | -0.14 | -0.19 | -0.97 | -0.25 | 0.03 | 0.01 | -0.09 | 0.03 | 0.11 | 0.13 | 0.16 | 0.03 | 0.09 | 0.05 | -0.04 | 0.06 | 0.04 | -0.16 | -0.07 | 0.01 | 0.05 | -0.04 |
Weighted Avg Shares Out | 34.62M | 34.52M | 34.33M | 34.21M | 34.07M | 33.19M | 31.42M | 27.43M | 24.33M | 17.68M | 17.49M | 17.63M | 17.60M | 17.37M | 16.90M | 16.07M | 15.32M | 14.54M | 13.92M | 13.75M | 13.63M | 13.20M | 13.45M | 13.90M | 13.88M | 13.88M | 8.19M | 7.66M | 4.35M |
Weighted Avg Shares Out (Dil) | 34.62M | 34.52M | 34.33M | 34.21M | 34.07M | 34.37M | 31.43M | 27.45M | 27.75M | 17.76M | 17.67M | 17.79M | 17.67M | 17.37M | 17.84M | 17.09M | 17.68M | 16.91M | 15.75M | 16.80M | 13.63M | 14.41M | 14.76M | 16.07M | 13.88M | 13.88M | 8.44M | 7.66M | 4.35M |
Apyx Medical Corporation Launches the "Renewing Lives" Give-Back Campaign Providing Treatments with Renuvion to Benefit Physical Appearance and Mental Health
Apyx Medical Corporation (APYX) Q1 2024 Earnings Call Transcript
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users' Summit
Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript
Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024
Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting
Source: https://incomestatements.info
Category: Stock Reports